MedPath

Randomised Controlled Trial Of Intravitreal Triamcinolone In Patients With Diabetic Macular Oedema Refractory To Laser Treatment

Phase 1
Conditions
Diabetic macular oedema affecting vision and refractory to laser treatment
Registration Number
EUCTR2005-000397-45-GB
Lead Sponsor
Queen's Medical centre
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

: -
All eyes with persistent CSME involving the center of the fovea as judged by slit lamp biomicroscopy and confirmed by active fluorescein leakage on FFA
All eyes with previous focal or at least one session of grid laser treatment with the last one being at least 3 months prior to the examaination and deemed to be complete by one of the observers masked to the eventual randomisation -
patients could be phakic or pseudophakic
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Excessive ischaemic diabetic maculopathy as judged clinically and/or on fluorescein angiography by >75% destruction of the outline of the foveal avscular zone (FAZ)
- patients with large plaques of sub-foveal exudates
- patients with active neovascular disease
-patients with high blood pressure (> 180/110)
-patients with documented renal disease
- patients on non steroidal antiinflammatories, systemic prednisolone, methotrexate, diamox. low dose aspirin is not an exclusion criteria and will be allowed on the trial
-all patients on warfarin
-coexisting glaucoma
-history of increased IOP on steroid drops or tablets or ocular hypertension
-patients with any other significant ocular pathology affecting the macula eg age related macular degenration

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath